课题基金 / 基金详情

Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity

Mechanisms of IL-6 mediated T cell pathogenesis in autoimmunity
IL-6介导的自身免疫T细胞发病机制
批准号:
10204509
负责人:
Jane Hoyt Buckner
金额:
$210.02万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-05-04 至 2023-03-31

项目摘要

项目成果

Jane Hoyt Buckner的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT ABSTRACT The IL-6 signaling pathway is dysregulated in autoimmunity in part through increased expression of the membrane bound IL-6R (mbIL-6R). The central hypothesis for the proposed studies is that elevated mbIL-6R expression leads to altered T cell fate and function resulting in pathogenic autoreactive T cells due to changes in the magnitude and balance of STAT1 and STAT3 phosphorylation. The following three Specific Aims will address this hypothesis. Aim 1 studies will determine the regulation of mbIL-6R expression in T cells from type 1 diabetes (T1D), relapsing remitting multiple sclerosis (RRMS) and rheumatoid arthritis (RA) subjects at the genetic, transcriptional, translational and post-translation level, focusing on the contribution of the IL6RAsp358Ala variant and ADAM17 mediated shedding. Aim 2 studies will determine how increased mbIL-6R alters the magnitude and balance of STAT1 and STAT3 phosphorylation and how these changes influence the T cell response with respect to lineage commitment, homing and response to regulation. These studies will take advantage of a cohort of healthy subjects with genetically determined mbIL-6R expression levels. Aim 3 studies will determine the impact of elevated mbIL-6R expression on both total T cells and autoreactive T cells in T1D, RRMS and RA. The primary endpoints will be T cell lineage commitment, transcriptional profile, and response to regulation. This aim will also determine the effect of elevated mbIL-6R expression on the islet specific T cell response to tocilizumab in T1D. The studies proposed in this application are appropriate for the “High Priority Immunology Grant (R01)” mechanism as it is research investigating the immunological mechanisms of autoimmune disease pathogenesis using well-defined human cohorts, high resolution immunophenotyping and systems immunology. These studies will advance our understanding of how subtle alterations in IL-6 signaling, contribute to the development and potentiation of autoimmunity.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3389/fimmu.2022.972121
发表时间: 2022
期刊: Frontiers in immunology
影响因子: 7.3
作者: []
通讯作者:
DOI: 10.1172/jci.insight.159436
发表时间: 2022-11-22
期刊: JCI INSIGHT
影响因子: 8
作者: [Speake, Cate, Habib, Tania, Lambert, Katharina, Hundhausen, Christian, Lord, Sandra, Dufort, Matthew J., Skinner, Samuel O., Hu, Alex, Kinsman, MacKenzie, Jones, Britta E., Maerz, Megan D., Tatum, Megan, Hocking, Anne M., Nepom, Gerald T., Greenbaum, Carla J., Buckner, Jane H.]
通讯作者: Buckner, Jane H.
Clinical and experimental treatment of type 1 diabetes.
1 型糖尿病的临床和实验治疗。
DOI: 10.1093/cei/uxac077
发表时间: 2022
期刊: Clinical and experimental immunology
影响因子: 4.6
作者: [Long,SAlice, Buckner,JaneH]
通讯作者: Buckner,JaneH
Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease
T cells promoting transitions toward autoimmunity
Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease (Admin Supp)
Harnessing engineered T regulatory cells to promote beta cell health in T1D
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis